In a recent pilot trial of 11 active pSS patients, the JAK1 and JAK2 inhibitor, baricitinib, showed promise in reducing immune cell infiltration and improving clinical manifestations, although controlled trials are needed for validation (Bai et al., 2022). The gene discussed is JAK1; the disease is peeling skin syndrome.